Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vor Biopharma Inc (NQ: VOR )

0.9539 +0.0339 (+3.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 95,798
Open 1.000
Bid (Size) 0.9301 (3)
Ask (Size) 1.000 (14)
Prev. Close 0.9200
Today's Range 0.9207 - 1.000
52wk Range 0.7000 - 3.140
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
VOR Stock Earnings: Vor Biopharma Beats EPS for Q2 2024
VOR stock results show that Vor Biopharma beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire

Performance

YTD
-57.22%
-57.22%
1 Month
+0.96%
+0.96%
3 Month
-38.66%
-38.66%
6 Month
-50.58%
-50.58%
1 Year
-65.44%
-65.44%

More News

Read More
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Vor Biopharma: Q4 Earnings Insights
Via Benzinga
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
VOR Stock Earnings: Vor Biopharma Beats EPS for Q1 2024
Via InvestorPlace
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
From Vor Biopharma
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
Via InvestorPlace
VOR Stock Earnings: Vor Biopharma Beats EPS for Q4 2023
Via InvestorPlace
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit
From Vor Biopharma
Via GlobeNewswire
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
From Vor Biopharma
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.